Bertram Pitt
Professor Emeritus of Internal Medicine, Medical School
Email:
[email protected]
Available to mentor
Bertram Pitt
Professor Emeritus/a
Manage Your Profile
Center Memberships
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
-
Center MemberMM-PKUHSC Joint Institute
Recent Publications
-
Ostrominski JW, Lu H, Claggett BL, Desai AS, Jhund PS, Henderson AD, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Brinker M, Scalise A, De Sanctis Y, Hofmeister L, McMurray JJV, Solomon SD, Vaduganathan M. Diabetes Care, 2026 Nov 1; 49 (11): e184 - e187.Journal ArticleHypokalemia and New-Onset Diabetes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
DOI:10.2337/dc26-1305 PMID: PMC13690994 -
Pourafshar N, Nam C, Madapoosi SS, Choi MJ, Shah S, Pitt B, Xiong L, Rossignol P, Unwin R, Testani J, Wilcox CS. Hypertension, 2026 Nov 1; 83 (11): e27712Journal ArticleIntrarenal Determinants of GFR Decline During Loop Diuretic Therapy
DOI:10.1161/HYPERTENSIONAHA.126.27712 PMID: 42670726 -
Lu H, Schneider SR, Pabón MA, Claggett BL, Miao MZ, Desai AS, Jhund PS, Henderson A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD, Vaduganathan M. Jacc Heart Failure, 2026 Nov 1; 14 (11):Journal ArticleSleep Apnea in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
DOI:10.1016/j.jchf.2026.103187 PMID: 42340295 -
Stanger L, Goerger K, Zhang X, Yalavarthi P, Rickenberg A, Yamaguchi A, Flores Nascimento M, Kilgore A, Kim H, Wu X, Guo Y, Dahlgren AR, Zhang J, Shavit JA, Pitt B, Chen YE, Holinstat M. J Clin Invest, 2026 Oct 13;Journal ArticleSGLT1/2 inhibitor sotagliflozin, but not SGLT2-selective inhibitor empagliflozin, attenuates platelet activation and thrombosis.
DOI:10.1172/JCI201899 PMID: 42873976 -
Rao VS, Ivey-Miranda JB, Cox ZL, Wilson FP, Petrie MC, Sarnak M, Wilcox CS, Pitt B, McCallum W, Testani JM. European Heart Journal, 2026 Oct 7; 47 (38): 5558 - 5568.Journal ArticleBlood aldosterone concentrations and effects of mineralocorticoid receptor antagonists in heart failure
DOI:10.1093/eurheartj/ehag440 PMID: 42301739 -
Lund LH, Pitt B. European Heart Journal, 2026 Oct 7; 47 (38): 5501 - 5503.Journal ArticleBrain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis
DOI:10.1093/eurheartj/ehag450 PMID: 42390477 -
Aggarwal R, Bhatt DL, Szarek M, Davies MJ, Girard M, Hardin MB, Pitt B, Steg G. Canadian Journal of Cardiology, 2026 Oct 2; 42 (10): s132 - s133.Journal ArticleP206 CONSISTENT HEART FAILURE BENEFITS OF SOTAGLIFLOZIN ACROSS BASELINE HIGH SENSITIVITY C-REACTIVE PROTEIN: INSIGHTS FROM THE SCORED TRIAL
DOI:10.1016/j.cjca.2026.07.197 -
Wang N, Claggett BL, Pfeffer MA, Ferreira JP, Zannad F, Pitt B, Packer M, Docherty KF, McMurray JJV, Solomon SD, Vaduganathan M. Nature Medicine, 2026 Oct 1; 32 (10): 3874 - 3883.Journal ArticleShort-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium
DOI:10.1038/s41591-026-04623-z PMID: 42675244
Featured News & Stories
Health Lab
Could a diabetes medication be the next wonder drug?
Researchers identified how sotagliflozin may reduce heart attack and stroke risk, potentially offering benefits beyond diabetes care
